We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$261M
1-Year Est. Return
78.99%
This Fund
S&P 500
This Quarter
Est. Return
+4.66%
1 Year Est. Return
+78.99%
3 Year Est. Return
+177.36%
5 Year Est. Return
+206.33%
10 Year Est. Return
+684.02%
AUM
$968M
AUM Growth
+$854M
(+755%)
Cap. Flow
+$792M
Cap. Flow
% of AUM
81.83%
Top 10 Holdings %
Top 10 Hldgs %
57.56%
Holding
371
New
110
Increased
49
Reduced
126
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EQM
EQM Midstream Partners, LP
EQM
|
+$80.7M |
| 2 |
ETP
Energy Transfer Partners, L.P.
ETP
|
+$75.4M |
| 3 |
MPLX
MPLX
|
+$75.1M |
| 4 |
Marathon Petroleum
MPC
|
+$60.6M |
| 5 |
Williams Companies
WMB
|
+$40.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VPU
Vanguard Utilities ETF
VPU
|
+$1.7M |
| 2 |
Vanguard Energy ETF
VDE
|
+$1.28M |
| 3 |
iShares MSCI India ETF
INDA
|
+$1.24M |
| 4 |
Fidelity MSCI Financials Index ETF
FNCL
|
+$1.04M |
| 5 |
Incyte
INCY
|
+$637K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 76.95% |
| 2 | Miscellaneous | 14.11% |
| 3 | Healthcare | 7.43% |
| 4 | Utilities | 1.17% |
| 5 | Financials | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RETA
51
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $976K | 0.1% |
11,939
-8,545
| -42% | -$602K |
|
52
Vertex Pharmaceuticals
VRTX
$130B
| $974K | 0.1% |
5,051
+340
| +7% | +$60.5K |
|
53
Omeros
OMER
$1.32B
| $970K | 0.1% |
39,755
+2,679
| +7% | +$59.7K |
|
54
Neurocrine Biosciences
NBIX
$15.4B
| $962K | 0.1% |
7,823
+527
| +7% | +$59.8K |
|
|
SGEN
55
DELISTED
Seagen Inc. Common Stock
SGEN
| $922K | 0.1% |
11,953
+805
| +7% | +$59.3K |
|
56
Biogen
BIIB
$32.1B
| $905K | 0.09% |
2,561
+173
| +7% | +$59.6K |
|
|
MNTA
57
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $895K | 0.09% |
34,033
+2,293
| +7% | +$62K |
|
58
Gilead Sciences
GILD
$185B
| $886K | 0.09% |
11,485
+741
| +7% | +$56K |
|
|
CELG
59
DELISTED
Celgene Corp
CELG
| $880K | 0.09% |
9,832
+673
| +7% | +$59.5K |
|
60
United Therapeutics
UTHR
$21.2B
| $877K | 0.09% |
6,856
+462
| +7% | +$57.1K |
|
61
Ionis Pharmaceuticals
IONS
$7.67B
| $853K | 0.09% |
16,532
+1,114
| +7% | +$52.3K |
|
62
Nektar Therapeutics
NKTR
$2.36B
| $846K | 0.09% |
925
+62
| +7% | +$52.9K |
|
63
BioMarin Pharmaceuticals
BMRN
$12.7B
| $844K | 0.09% |
8,700
+586
| +7% | +$58.5K |
|
64
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$15.2B
| $838K | 0.09% |
+9,698
| New | +$833K |
|
65
Public Service Enterprise Group
PEG
$35.3B
| $818K | 0.08% |
+15,489
| New | +$809K |
|
66
Travere Therapeutics
TVTX
$6.03B
| $806K | 0.08% |
28,067
+1,891
| +7% | +$54.1K |
|
67
Ironwood Pharmaceuticals
IRWD
$729M
| $778K | 0.08% |
50,303
+3,390
| +7% | +$53.6K |
|
68
Arrowhead Research
ARWR
$9.56B
| $758K | 0.08% |
39,546
-29,041
| -42% | -$477K |
|
69
Rigel Pharmaceuticals
RIGL
$860M
| $751K | 0.08% |
23,402
+1,603
| +7% | +$48.1K |
|
|
XLRN
70
DELISTED
Acceleron Pharma
XLRN
| $750K | 0.08% |
13,104
-9,365
| -42% | -$460K |
|
71
Halozyme
HALO
$12.5B
| $749K | 0.08% |
41,199
+2,776
| +7% | +$48.6K |
|
|
72
Incyte
INCY
$25.5B
| $742K | 0.08% |
742
-9,282
| -93% | -$637K |
|
|
VPU
73
Vanguard Utilities ETF
VPU
$8.07B
| $735K | 0.08% |
6,238
-14,307
| -70% | -$1.7M |
|
|
TSRO
74
DELISTED
TESARO, Inc.
TSRO
| $725K | 0.07% |
18,590
+1,273
| +7% | +$44.9K |
|
75
Ultragenyx Pharmaceutical
RARE
$1.31B
| $721K | 0.07% |
9,441
+647
| +7% | +$52.6K |
|
Similar funds
BW
HFS
NFG
NI
FAM
RAM
TAM
SBCM
Virtus ETF Advisers's Q3 2018 Portfolio in Review
As of Q3 2018, Virtus ETF Advisers held 371 positions worth $968M, up 755% from $113M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Virtus ETF Advisers deployed $792M of net new capital in Q3 2018, opening 110 new positions and adding to 49 existing holdings. Its largest new stake was EQM Midstream Partners, LP: 1,479,454 shares worth $78.1M.
By sector, the portfolio is most concentrated in Energy at 77% of assets, up from 0.35% a quarter earlier, followed by Miscellaneous and Healthcare.
On the sell side, the largest reduction was Vanguard Utilities ETF, an estimated $1.7M trimmed.
- Virtus ETF Advisers's largest Q3 2018 buy was EQM Midstream Partners, LP: 1,479,454 shares worth $78.1M.
- Virtus ETF Advisers added most to Marathon Petroleum in Q3 2018, an estimated $60.6M increase.
- Virtus ETF Advisers's biggest Q3 2018 reduction was Vanguard Utilities ETF, cutting an estimated $1.7M.
- Virtus ETF Advisers fully exited iShares MSCI India ETF in Q3 2018, selling an estimated $1.24M.
- Virtus ETF Advisers's ten largest holdings make up 58% of its $968M portfolio in Q3 2018.
- Virtus ETF Advisers opened 110 new positions and closed 30 in Q3 2018.
- Virtus ETF Advisers's portfolio value rose 755% quarter-over-quarter to $968M.
Based on Virtus ETF Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.